FDA grants accelerated approval for Tzield to delay insulin loss in children with newly diagnosed Stage 3 type 1 diabetes

The U.S. Food and Drug Administration issued an accelerated approval on June 12, 2026 for Tzield (teplizumab) to slow the decline of insulin production in pediatric patients aged 8 to 17 who have recently been diagnosed with Stage 3 type 1 diabetes.

This marks the first time the agency has approved a therapy specifically for this stage of the disease in children, offering a new option for families confronting rapid disease progression.

Tzield had previously been cleared to postpone the onset of Stage 3 diabetes in adults and younger patients with Stage 2 disease. The new indication was supported by a controlled clinical trial that demonstrated a statistically significant benefit on a key biomarker of insulin secretion.

The approval was granted through the FDA’s accelerated pathway, reflecting the agency’s assessment of a substantial unmet need and the drug’s favorable safety and efficacy profile.